サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1317917

GLP-1受容体作動薬市場：製品、薬効クラス、投与経路、流通チャネル、用途別-2023-2030年の世界予測

GLP-1 Receptor Agonist Market by Product, Drug Class, Route of Administration, Distribution Channel, Application - Cumulative Impact of COVID-19, Russia Ukraine Conflict, and High Inflation - Global Forecast 2023-2030
出版日: | 発行: 360iResearch | ページ情報: 英文 187 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
GLP-1受容体作動薬市場：製品、薬効クラス、投与経路、流通チャネル、用途別-2023-2030年の世界予測
出版日: 2023年06月12日
発行: 360iResearch
ページ情報: 英文 187 Pages
納期: 即日から翌営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

GLP-1受容体作動薬の世界市場は、2023年に44億4,736万米ドル、CAGR 11.19%で大きく成長し、2030年には93億8,786万米ドルに達すると予測されています。

FPNVポジショニング・マトリックス

FPNVポジショニングマトリックスは世界のGLP-1受容体作動薬市場を評価するために不可欠です。事業戦略と製品満足度の主要指標を調査することで、ベンダーの包括的な評価を提供し、ユーザーは特定のニーズに基づいた情報をもとに意思決定を行うことができます。この高度な分析により、ベンダーは成功の度合いが異なる4つの象限に整理されます：フォアフロント（F）、パスファインダー（P）、ニッチ（N）、バイタル（V）です。

市場シェア分析

市場シェア分析では、特定の市場領域におけるベンダーの現状を洞察することができます。全体的な収益、顧客基盤、その他の主要指標に対するベンダーの貢献度を比較することで、企業が市場シェアを争う際に、自社の業績や直面している状況をより深く理解することができます。また、本分析では、調査した基準年において、特定のセクターがどの程度競合しているのか、蓄積、断片化の優位性、合併の特徴についても明らかにしています。

本レポートは、以下のポイントに関する洞察を提供します：

1.市場の浸透度：主要企業が提供する市場に関する包括的な情報を提供します。

2.市場の発展：有利な新興市場に関する詳細情報を提供し、市場の成熟セグメントにおける浸透度を分析します。

3.市場の多様化：新製品の上市、未開発地域、最近の開発、投資に関する詳細情報を提供します。

4.市場の動向：COVID-19、ロシア・ウクライナ紛争、高インフレの累積的な影響を包括的に理解することができます。

5.競合の評価と情報：主要企業の市場シェア、戦略、製品、認証、規制状況、特許状況、製造能力を網羅的に評価します。

6.製品開発およびイノベーション：将来技術、研究開発活動、画期的な製品開発に関する知的洞察を提供します。

本レポートは、以下のような質問にお答えします：

1.GLP-1受容体作動薬の世界市場規模および予測は？

2.予測期間中、世界のGLP-1受容体作動薬市場を形成するCOVID-19の阻害要因と影響は？

3.GLP-1受容体作動薬の世界市場において予測期間中に投資すべき製品/セグメント/アプリケーション/分野は？

4.GLP-1受容体作動薬の世界市場における競争戦略は？

5.GLP-1受容体作動薬の世界市場における技術動向と規制の枠組みは？

6.GLP-1受容体作動薬の世界市場における主要ベンダーの市場シェアは？

7.GLP-1受容体作動薬の世界市場への参入には、どのような形態や戦略的な動きが適していると考えられるか？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

  • 市場力学
    • 促進要因
      • 糖尿病患者数の増加と最近の2型糖尿病治療の進歩
      • 新しい医薬品の承認数が増加
      • 糖尿病を抑制するための政府の啓発キャンペーン
    • 抑制要因
      • GLP-1受容体作動薬医薬品の特許期限切れ
    • 機会
      • 新製品の発売の増加と強力な医薬品パイプラインの継続的な開発
      • 商品化権獲得に向けたコラボレーション活動を中心に展開
    • 課題
      • 腎障害、膵炎、糖尿病性ケトアシドーシスなどの重度のリスクと制限
  • 市場動向
  • COVID-19の累積的な影響
  • ロシア・ウクライナ紛争の累積的影響
  • 高インフレの累積的影響
  • ポーターのファイブフォース分析
  • バリューチェーンとクリティカルパス分析
  • 規制の枠組み
  • 顧客のカスタマイズ

第6章 GLP-1受容体作動薬市場：製品別

  • ビデュリオン
  • オゼンピック
  • サクセンダ
  • トルリシティ
  • ビクトーザ

第7章 GLP-1受容体作動薬市場薬物クラス別

  • アルビグルチド
  • デュラグルチド
  • エクセナチド
  • リラグルチド
  • リキシセナチド
  • セマグルチド

第8章 GLP-1受容体作動薬市場：投与経路別

  • オーラル
  • 非経口

第9章 GLP-1受容体作動薬市場：流通チャネル別

  • 病院薬局
  • オンライン薬局
  • 小売薬局

第10章 GLP-1受容体作動薬市場：用途別

  • 肝硬変
  • 非アルコール性脂肪性肝炎
  • 肥満
  • 2型糖尿病

第11章 南北アメリカのGLP-1受容体作動薬市場

  • アルゼンチン
  • ブラジル
  • カナダ
  • メキシコ
  • 米国

第12章 アジア太平洋地域のGLP-1受容体作動薬市場

  • オーストラリア
  • 中国
  • インド
  • インドネシア
  • 日本
  • マレーシア
  • フィリピン
  • シンガポール
  • 韓国
  • 台湾
  • タイ
  • ベトナム

第13章 欧州・中東・アフリカのGLP-1受容体作動薬市場

  • デンマーク
  • エジプト
  • フィンランド
  • フランス
  • ドイツ
  • イスラエル
  • イタリア
  • オランダ
  • ナイジェリア
  • ノルウェー
  • ポーランド
  • カタール
  • ロシア
  • サウジアラビア
  • 南アフリカ
  • スペイン
  • スウェーデン
  • スイス
  • トルコ
  • アラブ首長国連邦
  • 英国

第14章 競合情勢

  • FPNVポジショニングマトリクス
  • 市場シェア分析：主要企業別
  • 競合シナリオ分析：主要企業別

第15章 掲載企業一覧

第16章 付録

  • ディスカッションガイド
  • ライセンスと価格について
図表

LIST OF FIGURES

  • FIGURE 1. GLP-1 RECEPTOR AGONIST MARKET RESEARCH PROCESS
  • FIGURE 2. GLP-1 RECEPTOR AGONIST MARKET SIZE, 2022 VS 2030
  • FIGURE 3. GLP-1 RECEPTOR AGONIST MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLP-1 RECEPTOR AGONIST MARKET SIZE, BY PRODUCT, 2022 VS 2030 (%)
  • FIGURE 5. GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2022 VS 2030 (%)
  • FIGURE 6. GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2022 VS 2030 (%)
  • FIGURE 7. GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2022 VS 2030 (%)
  • FIGURE 8. GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2022 VS 2030 (%)
  • FIGURE 9. GLP-1 RECEPTOR AGONIST MARKET SIZE, BY REGION, 2022 VS 2030 (%)
  • FIGURE 10. GLP-1 RECEPTOR AGONIST MARKET DYNAMICS
  • FIGURE 11. GLP-1 RECEPTOR AGONIST MARKET SIZE, BY PRODUCT, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 12. GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 13. GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 14. GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 15. GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 16. AMERICAS GLP-1 RECEPTOR AGONIST MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 17. UNITED STATES GLP-1 RECEPTOR AGONIST MARKET SIZE, BY STATE, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC GLP-1 RECEPTOR AGONIST MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 20. GLP-1 RECEPTOR AGONIST MARKET, FPNV POSITIONING MATRIX, 2022
  • FIGURE 21. GLP-1 RECEPTOR AGONIST MARKET SHARE, BY KEY PLAYER, 2022

LIST OF TABLES

  • TABLE 1. GLP-1 RECEPTOR AGONIST MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2022
  • TABLE 3. GLP-1 RECEPTOR AGONIST MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLP-1 RECEPTOR AGONIST MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 5. GLP-1 RECEPTOR AGONIST MARKET SIZE, BY BYDUREON, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 6. GLP-1 RECEPTOR AGONIST MARKET SIZE, BY OZEMPIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 7. GLP-1 RECEPTOR AGONIST MARKET SIZE, BY SAXENDA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 8. GLP-1 RECEPTOR AGONIST MARKET SIZE, BY TRULICITY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLP-1 RECEPTOR AGONIST MARKET SIZE, BY VICTOZA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 11. GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ALBIGLUTIDE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DULAGLUTIDE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLP-1 RECEPTOR AGONIST MARKET SIZE, BY EXENATIDE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLP-1 RECEPTOR AGONIST MARKET SIZE, BY LIRAGLUTIDE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLP-1 RECEPTOR AGONIST MARKET SIZE, BY LIXISENATIDE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLP-1 RECEPTOR AGONIST MARKET SIZE, BY SEMAGLUTIDE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 18. GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLP-1 RECEPTOR AGONIST MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 21. GLP-1 RECEPTOR AGONIST MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLP-1 RECEPTOR AGONIST MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 25. GLP-1 RECEPTOR AGONIST MARKET SIZE, BY LIVER CIRRHOSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLP-1 RECEPTOR AGONIST MARKET SIZE, BY NON-ALCOHOLIC STEATOHEPATITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLP-1 RECEPTOR AGONIST MARKET SIZE, BY OBESITY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLP-1 RECEPTOR AGONIST MARKET SIZE, BY TYPE 2 DIABETES MELLITUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS GLP-1 RECEPTOR AGONIST MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS GLP-1 RECEPTOR AGONIST MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 31. AMERICAS GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 32. AMERICAS GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 33. AMERICAS GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 34. AMERICAS GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 35. ARGENTINA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 36. ARGENTINA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 37. ARGENTINA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 38. ARGENTINA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 39. ARGENTINA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 40. BRAZIL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 41. BRAZIL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 42. BRAZIL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 43. BRAZIL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 44. BRAZIL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 45. CANADA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 46. CANADA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 47. CANADA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 48. CANADA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 49. CANADA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 50. MEXICO GLP-1 RECEPTOR AGONIST MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 51. MEXICO GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 52. MEXICO GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 53. MEXICO GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 54. MEXICO GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 55. UNITED STATES GLP-1 RECEPTOR AGONIST MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 56. UNITED STATES GLP-1 RECEPTOR AGONIST MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 57. UNITED STATES GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 58. UNITED STATES GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 59. UNITED STATES GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 60. UNITED STATES GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 61. ASIA-PACIFIC GLP-1 RECEPTOR AGONIST MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 62. ASIA-PACIFIC GLP-1 RECEPTOR AGONIST MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 63. ASIA-PACIFIC GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 64. ASIA-PACIFIC GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 65. ASIA-PACIFIC GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 66. ASIA-PACIFIC GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 67. AUSTRALIA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 68. AUSTRALIA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 69. AUSTRALIA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 70. AUSTRALIA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 71. AUSTRALIA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 72. CHINA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 73. CHINA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 74. CHINA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 75. CHINA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 76. CHINA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 77. INDIA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 78. INDIA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 79. INDIA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 80. INDIA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 81. INDIA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 82. INDONESIA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 83. INDONESIA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 84. INDONESIA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 85. INDONESIA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 86. INDONESIA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 87. JAPAN GLP-1 RECEPTOR AGONIST MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 88. JAPAN GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 89. JAPAN GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 90. JAPAN GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 91. JAPAN GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 92. MALAYSIA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 93. MALAYSIA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 94. MALAYSIA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 95. MALAYSIA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 96. MALAYSIA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 97. PHILIPPINES GLP-1 RECEPTOR AGONIST MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 98. PHILIPPINES GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 99. PHILIPPINES GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 100. PHILIPPINES GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 101. PHILIPPINES GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 102. SINGAPORE GLP-1 RECEPTOR AGONIST MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 103. SINGAPORE GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 104. SINGAPORE GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 105. SINGAPORE GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 106. SINGAPORE GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 107. SOUTH KOREA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 108. SOUTH KOREA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 109. SOUTH KOREA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 110. SOUTH KOREA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 111. SOUTH KOREA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 112. TAIWAN GLP-1 RECEPTOR AGONIST MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 113. TAIWAN GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 114. TAIWAN GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 115. TAIWAN GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 116. TAIWAN GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 117. THAILAND GLP-1 RECEPTOR AGONIST MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 118. THAILAND GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 119. THAILAND GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 120. THAILAND GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 121. THAILAND GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 122. VIETNAM GLP-1 RECEPTOR AGONIST MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 123. VIETNAM GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 124. VIETNAM GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 125. VIETNAM GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 126. VIETNAM GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 133. DENMARK GLP-1 RECEPTOR AGONIST MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 134. DENMARK GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 135. DENMARK GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 136. DENMARK GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 137. DENMARK GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 138. EGYPT GLP-1 RECEPTOR AGONIST MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 139. EGYPT GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 140. EGYPT GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 141. EGYPT GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 142. EGYPT GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 143. FINLAND GLP-1 RECEPTOR AGONIST MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 144. FINLAND GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 145. FINLAND GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 146. FINLAND GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 147. FINLAND GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 148. FRANCE GLP-1 RECEPTOR AGONIST MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 149. FRANCE GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 150. FRANCE GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 151. FRANCE GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 152. FRANCE GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 153. GERMANY GLP-1 RECEPTOR AGONIST MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 154. GERMANY GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 155. GERMANY GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 156. GERMANY GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 157. GERMANY GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 158. ISRAEL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 159. ISRAEL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 160. ISRAEL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 161. ISRAEL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 162. ISRAEL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 163. ITALY GLP-1 RECEPTOR AGONIST MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 164. ITALY GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 165. ITALY GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 166. ITALY GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 167. ITALY GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 168. NETHERLANDS GLP-1 RECEPTOR AGONIST MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 169. NETHERLANDS GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 170. NETHERLANDS GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 171. NETHERLANDS GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 172. NETHERLANDS GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 173. NIGERIA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 174. NIGERIA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 175. NIGERIA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 176. NIGERIA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 177. NIGERIA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 178. NORWAY GLP-1 RECEPTOR AGONIST MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 179. NORWAY GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 180. NORWAY GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 181. NORWAY GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 182. NORWAY GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 183. POLAND GLP-1 RECEPTOR AGONIST MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 184. POLAND GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 185. POLAND GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 186. POLAND GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 187. POLAND GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 188. QATAR GLP-1 RECEPTOR AGONIST MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 189. QATAR GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 190. QATAR GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 191. QATAR GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 192. QATAR GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 193. RUSSIA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 194. RUSSIA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 195. RUSSIA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 196. RUSSIA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 197. RUSSIA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 198. SAUDI ARABIA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 199. SAUDI ARABIA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 200. SAUDI ARABIA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 201. SAUDI ARABIA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 202. SAUDI ARABIA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 203. SOUTH AFRICA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 204. SOUTH AFRICA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 205. SOUTH AFRICA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 206. SOUTH AFRICA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 207. SOUTH AFRICA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 208. SPAIN GLP-1 RECEPTOR AGONIST MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 209. SPAIN GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 210. SPAIN GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 211. SPAIN GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 212. SPAIN GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 213. SWEDEN GLP-1 RECEPTOR AGONIST MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 214. SWEDEN GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 215. SWEDEN GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 216. SWEDEN GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 217. SWEDEN GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 218. SWITZERLAND GLP-1 RECEPTOR AGONIST MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 219. SWITZERLAND GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 220. SWITZERLAND GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 221. SWITZERLAND GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 222. SWITZERLAND GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 223. TURKEY GLP-1 RECEPTOR AGONIST MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 224. TURKEY GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 225. TURKEY GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 226. TURKEY GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 227. TURKEY GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 228. UNITED ARAB EMIRATES GLP-1 RECEPTOR AGONIST MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 229. UNITED ARAB EMIRATES GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 230. UNITED ARAB EMIRATES GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 231. UNITED ARAB EMIRATES GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 232. UNITED ARAB EMIRATES GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 233. UNITED KINGDOM GLP-1 RECEPTOR AGONIST MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 234. UNITED KINGDOM GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 235. UNITED KINGDOM GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 236. UNITED KINGDOM GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 237. UNITED KINGDOM GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 238. GLP-1 RECEPTOR AGONIST MARKET, FPNV POSITIONING MATRIX, 2022
  • TABLE 239. GLP-1 RECEPTOR AGONIST MARKET SHARE, BY KEY PLAYER, 2022
  • TABLE 240. GLP-1 RECEPTOR AGONIST MARKET LICENSE & PRICING
目次
Product Code: MRR-B9334AD6C603

The Global GLP-1 Receptor Agonist Market is forecasted to grow significantly, with a projected USD 4,447.36 million in 2023 at a CAGR of 11.19% and expected to reach a staggering USD 9,387.86 million by 2030.

The Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and High Inflation is expected to have significant long-term effects on the Global GLP-1 Receptor Agonist Market. The ongoing research considers the changes in consumer behavior, supply chain disruptions, and government interventions caused by the pandemic. Similarly, the report considers the ongoing political and economic uncertainty in Eastern Europe caused by the Russia-Ukraine Conflict and its potential implications for demand-supply balances, pressure on pricing variants, and import/export and trading. Additionally, the report addresses the impact of High Inflation on the global economy and details fiscal policies measuring and reducing its effects on demand, supply, cash flow, and currency exchange.

Market Segmentation & Coverage:

This research report categorizes the Global GLP-1 Receptor Agonist Market in order to forecast the revenues and analyze trends in each of following sub-markets:

Based on Product, market is studied across Bydureon, Ozempic, Saxenda, Trulicity, and Victoza. The Bydureon is projected to witness significant market share during forecast period.

Based on Drug Class, market is studied across Albiglutide, Dulaglutide, Exenatide, Liraglutide, Lixisenatide, and Semaglutide. The Dulaglutide is projected to witness significant market share during forecast period.

Based on Route of Administration, market is studied across Oral and Parenteral. The Oral is projected to witness significant market share during forecast period.

Based on Distribution Channel, market is studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies. The Retail Pharmacies is projected to witness significant market share during forecast period.

Based on Application, market is studied across Liver Cirrhosis, Non-Alcoholic Steatohepatitis, Obesity, and Type 2 Diabetes Mellitus. The Liver Cirrhosis is projected to witness significant market share during forecast period.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Americas commanded largest market share of 38.75% in 2022, followed by Europe, Middle East & Africa.

Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make well-informed decisions. In this report, 2018 to 2021 are considered as historical years, 2022 is base year, 2023 is estimated year, and years from 2024 to 2030 are considered as forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix is essential for assessing the Global GLP-1 Receptor Agonist Market. It provides a comprehensive evaluation of vendors by examining key metrics within Business Strategy and Product Satisfaction, allowing users to make informed decisions based on their specific needs. This advanced analysis then organizes these vendors into four distinct quadrants, which represent varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital(V).

Market Share Analysis:

The Market Share Analysis offers an insightful look at the current state of vendors in a particular market space. By comparing vendor contributions to overall revenue, customer base, and other key metrics, we can give companies a greater understanding of their performance and what they are up against when competing for market share. The analysis also sheds light on just how competitive any given sector is about accumulation, fragmentation dominance, and amalgamation traits over the base year period studied.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players

2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes penetration across mature segments of the markets

3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments

4. Market Trends: Provides comprehensive understanding of the Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and the High Inflation

5. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players

6. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the Global GLP-1 Receptor Agonist Market?

2. What are the inhibiting factors and impact of COVID-19 shaping the Global GLP-1 Receptor Agonist Market during the forecast period?

3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global GLP-1 Receptor Agonist Market?

4. What is the competitive strategic window for opportunities in the Global GLP-1 Receptor Agonist Market?

5. What are the technology trends and regulatory frameworks in the Global GLP-1 Receptor Agonist Market?

6. What is the market share of the leading vendors in the Global GLP-1 Receptor Agonist Market?

7. What modes and strategic moves are considered suitable for entering the Global GLP-1 Receptor Agonist Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. GLP-1 Receptor Agonist Market, by Product, 2022 vs 2030
  • 4.3. GLP-1 Receptor Agonist Market, by Drug Class, 2022 vs 2030
  • 4.4. GLP-1 Receptor Agonist Market, by Route of Administration, 2022 vs 2030
  • 4.5. GLP-1 Receptor Agonist Market, by Distribution Channel, 2022 vs 2030
  • 4.6. GLP-1 Receptor Agonist Market, by Application, 2022 vs 2030
  • 4.7. GLP-1 Receptor Agonist Market, by Region, 2022 vs 2030

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increase in the number of diabetic patients and recent advancement in the treatment of Type 2 Diabetes Mellitus
      • 5.1.1.2. Growing number of approval for novel medications
      • 5.1.1.3. Government awareness campaigns to curb diabetes mellitus
    • 5.1.2. Restraints
      • 5.1.2.1. Patent expiry of GLP-1 receptor agonist drugs
    • 5.1.3. Opportunities
      • 5.1.3.1. Rising new product launches and ongoing development of strong medication pipeline
      • 5.1.3.2. Developing focus on the collaboration activities to obtain commercialization rights
    • 5.1.4. Challenges
      • 5.1.4.1. Severe risks and limitations such as renal impairment, pancreatitis, diabetic ketoacidosis
  • 5.2. Market Trends
  • 5.3. Cumulative Impact of COVID-19
  • 5.4. Cumulative Impact of Russia-Ukraine Conflict
  • 5.5. Cumulative Impact of High Inflation
  • 5.6. Porter's Five Forces Analysis
    • 5.6.1. Threat of New Entrants
    • 5.6.2. Threat of Substitutes
    • 5.6.3. Bargaining Power of Customers
    • 5.6.4. Bargaining Power of Suppliers
    • 5.6.5. Industry Rivalry
  • 5.7. Value Chain & Critical Path Analysis
  • 5.8. Regulatory Framework
  • 5.9. Client Customization

6. GLP-1 Receptor Agonist Market, by Product

  • 6.1. Introduction
  • 6.2. Bydureon
  • 6.3. Ozempic
  • 6.4. Saxenda
  • 6.5. Trulicity
  • 6.6. Victoza

7. GLP-1 Receptor Agonist Market, by Drug Class

  • 7.1. Introduction
  • 7.2. Albiglutide
  • 7.3. Dulaglutide
  • 7.4. Exenatide
  • 7.5. Liraglutide
  • 7.6. Lixisenatide
  • 7.7. Semaglutide

8. GLP-1 Receptor Agonist Market, by Route of Administration

  • 8.1. Introduction
  • 8.2. Oral
  • 8.3. Parenteral

9. GLP-1 Receptor Agonist Market, by Distribution Channel

  • 9.1. Introduction
  • 9.2. Hospital Pharmacies
  • 9.3. Online Pharmacies
  • 9.4. Retail Pharmacies

10. GLP-1 Receptor Agonist Market, by Application

  • 10.1. Introduction
  • 10.2. Liver Cirrhosis
  • 10.3. Non-Alcoholic Steatohepatitis
  • 10.4. Obesity
  • 10.5. Type 2 Diabetes Mellitus

11. Americas GLP-1 Receptor Agonist Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific GLP-1 Receptor Agonist Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa GLP-1 Receptor Agonist Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. FPNV Positioning Matrix
  • 14.2. Market Share Analysis, By Key Player
  • 14.3. Competitive Scenario Analysis, By Key Player

15. List of Company Mentioned

16. Appendix

  • 16.1. Discussion Guide
  • 16.2. License & Pricing